Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for cemiplimab - cutaneous squamous cell carcinoma

  1. Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)

    Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA802

  2. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    In development Reference number: GID-TA11869 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.

    Technology appraisal guidance
    In consultation

  4. Guidance and quality standards in consultation

    See a complete list of all our guidance and quality standards currently open for consultation

  5. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA802.

    Withdrawn guidance